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Abstract
Polo-like kinase 1 (Plk1) belongs to a family of conserved serine/threonine kinases with a polo-box
domain, which have similar but non-overlapping functions in the cell cycle progression. Plk1 plays
a key role to ensure the normal mitosis. Interestingly, overexpression of Plk1 is associated with
tumor development and could serve as a prognostic marker for many cancers. Due to Plk1
overexpression, several Plk1 inhibitors have been developed and tested for the cancer treatment.
However, in a recent study, it has been suggested that down-regulation of Plk1 could also induce
aneuploidy and tumor formation in vivo. Therefore, a normal level of Plk1 is important for mitosis.
And caution should be taken when Plk1 inhibitors are used in the clinical trial and their side effects
including tumorigenesis should be carefully evaluated.
Review
Polo-like kinases (Plks) are serine/threonine kinases with
an N-terminal kinase domain and a C-terminal polo-box
domain. The domain structure of this family is evolution-
ary conserved from yeast to mammals[1]. In mammals,
there are four different Plks that all participate in the cell
cycle regulation [2]. Plk1 is the best characterized member
in this group. Numerous lines of evidence demonstrate
that Plk1 plays critical roles in multiple stages of mitosis
(reviewed in [3]). Either up-regulated or down-regulated
Plk1 could induce mitotic defects that result in aneu-
ploidy and tumorigenesis. Therefore, balanced Plk1 levels
are important for normal mitosis. In this review, we will
summarize current understandings of the role of Plk1 in
mitosis, with emphasis on its association with tumorigen-
esis.
Multiple roles of Plk1 in mitotic progression
Plkl functions in almost every stage of mitosis, as evi-
denced by changing of its localization during mitotic pro-
gression. Plk1 localizes at the centrosomes during inter-
phase and prophase, and is found at kinetochores in pre-
metaphase and metaphase. It later relocates to spindles
during anaphase and finally resides at the midbody dur-
ing telophase [4-7]. This dynamic localization of Plk1 cor-
relates with several distinct functions of Plk1 that are
through its different substrates recognition and phospho-
rylation during mitosis. Plk1 directly promotes mitotic
entry by activating Cdc25C and Cdk1/Cyclin B complex
[8-10]. It contributes to centrosome maturation and
drives microtubule nucleation through phosphorylating
Nlp, Kizuna and Asp [11-14]. Plk1 facilitates kinetochore
assembly and potentially regulates of spindle assembly
checkpoint by interaction with INCENP, Bub1 and BubR1
[5,15-17]. Plk1 is also indispensable for the completion of
cytokinesis by regulating Ect2 and RhoA [18,19]. Consist-
ent with the critical role of Plk1 in mitosis, Plk1-deficient
mice are early embryonic lethal. Plk1-null embryos fail to
pass 8-cell stage and no mitotic cells were observed in
these embryos [20]. Although Plk1-null zygotes could go
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through three rounds of mitosis and develop to 8-cell
stage, it is most likely that maternal Plk1 protein and
mRNA are still sufficient for a few rounds of mitosis. Once
depleting the maternal material contributed Plk1 protein,
cell cycle is arrested.
Plk1 overexpression is associated with 
tumorigenesis
Proper cell cycle progression is critical for maintaining
genomic stability. Mitosis is particularly tightly regulated
as deregulated mitosis would lead to improper segrega-
tion of chromosomes. Checkpoints including G2/M
checkpoint, kinetochore and spindle checkpoint have
therefore evolved to ensure proper onset of mitosis and
correct transmission of genetic material to daughter cells
[21]. The mitotic progression is mainly promoted by cyc-
lin-dependent kinases and further controlled by several
critical mitotic kinases including Plk1 [22,23]. Therefore,
the expression level of these mitotic kinases must be
tightly regulated. Overexpression of these kinases can
override those mitotic checkpoints and lead to immature
cell division without proper chromosome alignment and
segregation, which will result in aneuploidy, one of the
major causes for tumorigenesis [24,25]. Because of this,
these mitotic kinases including Plk1 are often considered
as proto-oncogenes, whose overexpression is often
observed in tumor cells [26]. Meanwhile, aneuploidy and
tumorigenesis can also result from centrosome abnormal-
ity, particularly centrosome amplification defects [27,28].
Centrosome duplication and maturation regulated by
Plk1 occurs from late S phase to prophase [11]. Abnormal
centrosome amplification may lead to multipolar spin-
dles and results in unequal segregation of chromosomes
[29]. Thus, Plk1 overexpression may also increase the cen-
trosome size and/or centrosome number, which will also
lead to improper segregation of chromosomes, aneu-
ploidy, and tumorigenesis.
To date, overexpression of Plk1 has been observed in a
number of human cancers including non-small-cell lung
cancer [30], head and neck cancer [31], esophageal cancer
[32,33], gastric cancer [32,34,35], melanomas [36,37],
breast cancer[38], ovarian cancer [39], endometrial cancer
[40], colorectal cancer [41,42], glioma [43], papillary car-
cinoma [44], pancreatic cancer [45,46], prostate cancer
[47], hepatoma [48], leukemia and lymphoma [49,50],
bladder cancer [51], and thyroid cancer [52]. Many of
these studies have demonstrated that Plk1 overexpression
correlates with tumor progression and patient survival
rate in a variety of cancers [30-33,35-37,42,48-50]. There-
fore, Plk1 is proposed as a prognostic marker for human
cancers.
Although Plk1 is often overexpressed in human cancers,
the Plk1 gene is rarely amplified, indicating that transcrip-
tional or post-transcriptional regulation of Plk1 are
affected in cancer cells. The association of Plk1 overex-
pression with cancers could be explained as a result of
high mitotic index of tumor cells since Plk1 levels are cell
cycle-regulated with a peak during mitosis [4,7]. Indeed,
early studies of Plk1 in different fetal and adult tissues
have shown that Plk1 levels are much higher in thymus,
spleen and testis, which have more proliferating cells [53-
55]. However, Plk1 overexpression has been indicated as
the cause of tumor formation instead of being the conse-
quence of high mitotic index during tumor cell prolifera-
tion. Overexpression of Plk1 in NIH3T3 fibroblasts
transformed the cells into oncogenic foci in soft agar and
more importantly lead to tumor formation when injected
into nude mice [56].
Development of Plk1 inhibitors
Since Plk1 is considered as a "proto-oncogene", inhibi-
tion of Plk1 could be an effective treatment for cancers.
Several strategies of inhibiting Plk1 activity have thus
been tested in cancer therapeutic trials. One of the strate-
gies is to deplete the expression of Plk1 by using anti-sense
oligonucleotides (ASO) or small interfering RNA (siRNA)
to block Plk1 translation or transcription. This rationale
comes from the effect of Plk1 depletion in cell cultures,
which leads to mitotic arrest and apoptosis of the cells
[57,58]. To date, several groups have also shown success-
ful suppression of tumor growth by this approach in vivo.
For example, intravenous injection of Plk1 ASO signifi-
cantly suppressed growth of A549 cells in tumor
xenografts [59]. Similarly, Intravesical administration of
Plk1 siRNA suppressed bladder cancer growth in an ortho-
topic bladder cancer mouse model [60]. Plasmid-based
U6 promoter-driven short hairpin RNA has also been
demonstrated to be effective in suppressing growth of
HeLa S3 xenografts [61]. However, due to the intrinsic
problems including dose-limiting side effects, inadequate
penetration into the tumor tissues, and degradation by
endogenous nucleases, it is difficult to achieve a consist-
ently high efficacy [62,63]. Optimization of the delivery
system is ongoing, for example using ASO-loaded HSA
nanoparticles [64].
Using small molecules to inhibit Plk1 is another
approach, as these molecules are easier to be delivered
into cells and are less likely to be degraded. For most
chemical inhibitors, they are designed to suppress impor-
tant functional domains. For Plk1, one important domain
is the serine/threonine kinase domain at the N-terminus.
Same as other serine/threonine kinases, the activity of
Plk1 kinase domain requires ATP. Thus, ATP analogues
have been designed and screened for inhibiting Plk1. The
first identified inhibitor of this kind is scytonemin iso-
lated from cyanobacteria with an IC50  of 2 μM [65].
Recently, a much more specific ATP competitor, BI 2536,Cell Division 2009, 4:4 http://www.celldiv.com/content/4/1/4
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has been identified. It inhibits the kinase activity of Plk1
with an IC50 of only 0.83 nM. More importantly, this mol-
ecule displayed 1000-fold selectivity for Plk1 over 63
other kinases tested [66,67]. BI 2526 not only induced
mitotic arrest and apoptosis in a number of tumor cells,
but also suppressed the growth of human tumor
xenografts in nude mice [66]. Currently, a phase I clinical
trial is ongoing with the treatment of advanced solid
tumors [68]. Besides BI 2526, several other compounds
including thiophene benzimidazole compound 1 and
pyrimidine derivative DAP-81 have also been shown to
specifically inhibit Plk1 activity [69,70].
Besides ATP analogs, several non-ATP competitors were
identified to block substrates binding to Plk1 kinase
domain. For example, ON01910 inhibits Plk1 effectively
with an IC50 of 9–10 nM [71]. This drug potently induced
apoptosis in 151 tumor cell lines tested and inhibited
tumor growth of three human tumor xenografts in nude
mice. Currently, this drug is under evaluation in phase I
clinical trials [72]. Similarly, a non-ATP competitive
inhibitor TAL was recently identified that specifically
inhibits Plk1 over 93 other kinases with an IC50 of around
19 nM [73]. Using a structural-guided approach, a non-
ATP competitive inhibitor cyclapolin 1 was also identified
to inhibit Plk1 with an IC50 of 20 nM [74].
Except the kinase domain, the other important domain of
Plk1 is the C-terminal polo-box domain (PBD). This
domain is a phospho-amino acid binding motif
[10,75,76] that is essential for the substrate recognition
and localization of Plk1 to centrosomes, kinetochores,
and the midbody [77,78]. Chemical compounds that
block the PBD would thus block the functions of Plk1.
One advantage is that the PBD is not present in kinases
other than Plks. Therefore, it is unlikely that small mole-
cules targeting the PBD will affect other kinases. Based on
this hypothesis, the natural product thymoquinone and
the synthetic thymoquinone derivative Poloxin were
identified that inhibited Plk1 by interfering the PBD [79].
Although with less potency, these drugs provided the
proof of the principle that targeting PBD is a promising
approach.
One concern for all Plk1 inhibitors is that they inhibit
other Plks with similar potencies, most likely due to the
structural similarities between these four family members.
For example, besides inhibiting Plk1 with IC50 of 0.83 nM,
BI 2536 also inhibit Plk2 and Plk3 with IC50 3.5 nM and
9 nM respectively [66]. Such broad inhibition of all Plks
may have unexpected side effects as different Plks have
none overlapping roles in mitosis, and not all Plks are
overexpressed in cancers [80,81].
Loss of Plk1 also leads to tumor formation
Paradoxically, loss of Plk1 is also associated with tumor
formation. Several missense mutations of Plk1 have been
identified in different cancer cell lines with various tissue
origins [82]. These mutations locate at the C-terminal
PBD and suppress the interaction between Plk1 and
HSP90, a molecular chaperon that functions in protein
folding [83]. As a result, mutant Plk1 is unstable without
the chaperon, which leads to low expression levels of Plk1
in these cell lines. Since Plk1 is a key mitotic kinase, the
reduction of Plk1 may also induce mitotic defects that
lead to aneuploidy and tumorigenesis. This possibility has
been proven by a recent in vivo study [20]. In this study,
Plk1 heterozygous mice have been generated, in which
the expression level of Plk1 was significantly decreased. A
cohort of Plk1 wild type and heterozygous mice were
maintained and the tumor development was monitored.
Surprisingly, 30% of Plk1 heterozygous mice developed
tumors at an average of 13–14 months old, and this was a
3-fold increase of tumor incidence compared with that in
wild type mice. The major tumor type is lymphoma, prob-
ably due to the rapid proliferation of lymphocytes and the
requirement for high expression of Plk1 to maintain the
cell proliferation [55]. Moreover, correlated with the
tumor phenotype, analysis of pre-malignant splenocytes
displayed elevated aneuploidy in Plk1 heterozygous mice.
Considering the importance of Plk1 in every stage of mito-
sis, reduced Plk1 levels might not only delay centrosome
maturation and mitotic entry but also cause improper seg-
regation of chromosomes and arrest cytokinesis. These
events will eventually lead to aneuploidy and tumorigen-
esis. Thus, Plk1 can also be considered as a "haploinsuffi-
cient tumor repressor".
The tumorigenesis induced by either overexpression or
down-regulation of Plk1 suggests the level of Plk1 has to
be tightly regulated, which reflects its critical role in
mitotic progression. Excessive Plk1 will override the
mitotic checkpoint, amplify the centrosome abnormally,
and chromosomes will segregate without proper align-
ment or unequally. Insufficient Plk1 will also leads to
mitotic delay and improper separation of chromosome.
In both scenarios, aneuploidy and tumors will occur. Sim-
ilar associations of tumorigenesis with aberrant expres-
sion of other Plks and even other mitotic kinases were also
observed [26]. For example, the expression of Plk3 is
down-regulated in several human cancers [84-86] and
Plk3 is therefore considered as a tumor-suppressor gene.
Consistently, Plk3 knockout mice are viable and develop
tumors in various organs in advanced stage [87]. Plk4 is
another potential tumor suppressing gene residing at
chromosome 4q28 in human, a region where loss of het-
erozygosity (LOH) is common in hepatoma samples [88].
Plk4-null mice are embryonic lethal and Plk4 hetero-
zygous mice display 15-fold increase in incidence of liverCell Division 2009, 4:4 http://www.celldiv.com/content/4/1/4
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and lung cancers than that of wild type mice [89]. These
all suggest that the level of these kinases needs to be
tightly regulated.
Like Plk1, Aurora A, is another multi-functional kinase
involved in all stages of mitosis [90,91]. Overexpression
of Aurora A has been reported in a number of cancers
[92], and chemical compounds have been developed to
target Aurora A in cancer therapeutic trials. Similar as
Plk1, overexpression of Aurora A suppresses the mitotic
checkpoint, induces various mitotic defects and transfor-
mation of fibroblasts both in vitro and in vivo. Moreover,
like Plk1-null mice, Aurora A knockout mice fail to survive
after blastocyst stage [93,94]. More importantly, Aurora A
heterozygous mice with reduced Aurora A level are also
tumor prone with a significant increased incidence of
lymphoma. And lymphocytes from Aurora A hetero-
zygous mice display elevated aneuploidy [93]. The similar
phenotypes between Plk1 and Aurora A knockout mice
suggest that these two mitotic kinases work in a similar
pathway. Indeed, recent reports suggest that Plk1 is actu-
ally activated by Aurora A and its cofactor Bora before it
activates CDK1 and promotes mitotic entry [95,96].
Again, the similar tumor phenotypes of Plk1 and Aurora
A heterozygous mice suggest that balanced mitotic kinases
are important for maintaining genomic stability. Reduc-
ing the levels of these mitotic kinases long term may
induce tumorigenesis. Since a few drugs targeting Plks and
Aurora kinases are currently in the clinical trails for cancer
treatment, long term side effects including secondary
tumor formation should be carefully evaluated.
Concluding remarks
Plk1 is a critical kinase with multiple functions during
mitotic progression. Its expression level has to be precisely
regulated. Either overexpression or down-regulation of
Plk1 will lead to tumorigenesis. Considering several ongo-
ing clinical trials using Plk1 inhibitors, the side effects of
these drugs in inducing genomic instability should be
carefully observed.
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